Open-Label, Multicenter, Phase I/II, First-in-Human Trial of TK216: A First-Generation EWS::FLI1 Fusion Protein Antagonist in Ewing SarcomaPaul A. Meyers, Joseph A. Ludwig, Najat C. Daw et al.|Journal of Clinical Oncology|2024Cited by 36
The androgen receptor is a therapeutic target in desmoplastic small round cell sarcomaSalah-Eddine Lamhamedi-Cherradi, Joseph A. Ludwig|Nature Communications|2022Cited by 29